Shares of Moderna MRNA moved higher by 0.7% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 24.39% year over year to ($0.31), which beat the estimate of ($0.35).
Revenue of $66,351,000 higher by 407.15% from the same period last year, which beat the estimate of $27,430,000.
Outlook
Moderna hasn't issued any earnings guidance for the time being.
Moderna hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 05, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/oybp8b26
Price Action
Company's 52-week high was at $95.21
Company's 52-week low was at $11.54
Price action over last quarter: Up 33.62%
Company Profile
Moderna Inc is engaged in creating transformative medicines based on messenger RNA, or mRNA. It transfers the information stored in the genes to the cellular machinery that makes all the proteins required for life. The firm is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases. Its clinical trials include mRNA-1647, mRNA-1893, mRNA-4157, and mRNA-2416 among others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
